Overview

  • Product nameAnti-Apolipoprotein E antibody
    See all Apolipoprotein E primary antibodies
  • Description
    Rabbit polyclonal to Apolipoprotein E
  • SpecificityAb20874 is extremely low recognition of human Apo E. No data available regarding rat activity. We have data to indicate that this antibody may not cross react with Human. However, this has not been conclusively tested and expression levels may vary in certain cell lines/tissues.
  • Tested applicationsRID, Immunodiffusion, Immunoelectrophoresis, WB, IHC-Frmore details
  • Species reactivity
    Reacts with: Mouse, Rat
  • Immunogen

    Full length purified Mouse Apolipoprotein E from pooled mouse plasma high and very low density lipoproteins.

Applications

Our Abpromise guarantee covers the use of ab20874 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
RID Use at an assay dependent dilution.
Immunodiffusion Use at an assay dependent dilution.
Immunoelectrophoresis Use at an assay dependent dilution.
WB 1/500 - 1/1000. Predicted molecular weight: 36 kDa. Dilution optimised using Chromogenic detection.
IHC-Fr Use at an assay dependent dilution. PubMed: 20505763

Target

  • FunctionMediates the binding, internalization, and catabolism of lipoprotein particles. It can serve as a ligand for the LDL (apo B/E) receptor and for the specific apo-E receptor (chylomicron remnant) of hepatic tissues.
  • Tissue specificityOccurs in all lipoprotein fractions in plasma. It constitutes 10-20% of very low density lipoproteins (VLDL) and 1-2% of high density lipoproteins (HDL). APOE is produced in most organs. Significant quantities are produced in liver, brain, spleen, lung, adrenal, ovary, kidney and muscle.
  • Involvement in diseaseDefects in APOE are a cause of hyperlipoproteinemia type 3 (HLPP3) [MIM:107741]; also known as familial dysbetalipoproteinemia. Individuals with HLPP3 are clinically characterized by xanthomas, yellowish lipid deposits in the palmar crease, or less specific on tendons and on elbows. The disorder rarely manifests before the third decade in men. In women, it is usually expressed only after the menopause. The vast majority of the patients are homozygous for APOE*2 alleles. More severe cases of HLPP3 have also been observed in individuals heterozygous for rare APOE variants. The influence of APOE on lipid levels is often suggested to have major implications for the risk of coronary artery disease (CAD). Individuals carrying the common APOE*4 variant are at higher risk of CAD.
    Genetic variations in APOE are associated with Alzheimer disease type 2 (AD2) [MIM:104310]. It is a late-onset neurodegenerative disorder characterized by progressive dementia, loss of cognitive abilities, and deposition of fibrillar amyloid proteins as intraneuronal neurofibrillary tangles, extracellular amyloid plaques and vascular amyloid deposits. The major constituent of these plaques is the neurotoxic amyloid-beta-APP 40-42 peptide (s), derived proteolytically from the transmembrane precursor protein APP by sequential secretase processing. The cytotoxic C-terminal fragments (CTFs) and the caspase-cleaved products such as C31 derived from APP, are also implicated in neuronal death. Note=The APOE*4 allele is genetically associated with the common late onset familial and sporadic forms of Alzheimer disease. Risk for AD increased from 20% to 90% and mean age at onset decreased from 84 to 68 years with increasing number of APOE*4 alleles in 42 families with late onset AD. Thus APOE*4 gene dose is a major risk factor for late onset AD and, in these families, homozygosity for APOE*4 was virtually sufficient to cause AD by age 80. The mechanism by which APOE*4 participates in pathogenesis is not known.
    Defects in APOE are a cause of sea-blue histiocyte disease (SBHD) [MIM:269600]; also known as sea-blue histiocytosis. This disorder is characterized by splenomegaly, mild thrombocytopenia and, in the bone marrow, numerous histiocytes containing cytoplasmic granules which stain bright blue with the usual hematologic stains. The syndrome is the consequence of an inherited metabolic defect analogous to Gaucher disease and other sphingolipidoses.
    Defects in APOE are a cause of lipoprotein glomerulopathy (LPG) [MIM:611771]. LPG is an uncommon kidney disease characterized by proteinuria, progressive kidney failure, and distinctive lipoprotein thrombi in glomerular capillaries. It mainly affects people of Japanese and Chinese origin. The disorder has rarely been described in Caucasians.
  • Sequence similaritiesBelongs to the apolipoprotein A1/A4/E family.
  • Post-translational
    modifications
    Synthesized with the sialic acid attached by O-glycosidic linkage and is subsequently desialylated in plasma. O-glycosylated with core 1 or possibly core 8 glycans. Thr-307 is a minor glycosylation site compared to Ser-308.
    Glycated in plasma VLDL of normal subjects, and of hyperglycemic diabetic patients at a higher level (2-3 fold).
    Phosphorylation sites are present in the extracelllular medium.
  • Cellular localizationSecreted.
  • Information by UniProt
  • Database links
  • Alternative names
    • AD2 antibody
    • Alzheimer disease 2 antibody
    • Apo E antibody
    • Apo-E antibody
    • ApoE antibody
    • APOE_HUMAN antibody
    • APOEA antibody
    • Apolipoprotein E antibody
    • Apolipoprotein E3 antibody
    • ApolipoproteinE antibody
    • Apoprotein antibody
    • LDLCQ5 antibody
    • LPG antibody
    • MGC1571 antibody
    see all

Anti-Apolipoprotein E antibody images

  • Anti-Apolipoprotein E antibody (ab20874) + 20ug rat hippocampal lysate

    Secondary
    anti-rabit HRP-labeled secondary antibody

    Predicted band size : 36 kDa

    S Kanazir, Inst Biol Res, Yugoslavia

  • ab20874 staining Apolipoprotein E in rat brain tissue by Immunohistochemistry (Frozen sections). After fixation in 4% PFA in PBS (pH 7.4), brains were cryoprotected in 30% sucrose in PBS at +4°C, frozen, and thereafter kept at -80°C until used. For the immunostaining, brains were cryosectioned in 30 µm slices, collected in PBS (pH 7.4), and processed in a free-floating system. Slices were first incubated in the blocking solution (BS) containing 2% bovine serum albumin, 2% goat serum, and 0.1% Triton X-100 in PBS (pH 7.4) for 1 hour at room temperature, and thereafter with the primary antibody for 24–48 hours at +4°C in BS at a 1/1000 dilution. After washing in PBS, slices were incubated with the biotin-conjugated secondary antibody (1/4000) in BS, rinsed with PBS, and incubated with the avidin-peroxidase conjugate in BS for 1 hour at room temperature. The staining was detected using 3,3-diaminobenzidinetetrahydrochloride as a chromogen.

References for Anti-Apolipoprotein E antibody (ab20874)

This product has been referenced in:
  • Wooten JS  et al. The Influence of an Obesogenic Diet on Oxysterol Metabolism in C57BL/6J Mice. Cholesterol 2014:843468 (2014). WB ; Mouse . Read more (PubMed: 24672716) »
  • Skibinski CG  et al. Proteomic changes induced by effective chemopreventive ratios of n-3:n-6 fatty acids and tamoxifen against MNU-induced mammary cancer in the rat. Cancer Prev Res (Phila) 6:979-88 (2013). Read more (PubMed: 23880232) »

See all 10 Publications for this product

Product Wall

I have investigated this and am sorry to confirm that the concentration is not determined for ab20874 Apolipoprotein E antibody . Titer by RID (Radioimmunodiffusion) is determined which is 1:40.

Unpurified antibodies such as this one sold as...

Read More

Unfortunately, since Anti-Apolipoprotein E antibody (ab20874) is a Whole antiserum and has not been purified, we have not determined the concentration. We estimate that it will be between 1-10 mg/ml.

Here is the protocol we use in-house to m...

Read More

Thank you for your enquiry.

I can confirm that ab20874 antibody is sold as whole antiserum. Unpurified antibodies, such as those sold as whole antiserum, ascites or tissue culture supernatant will not have a concentration stated on the datashe...

Read More

Thank you for your reply.

I am sorry but xxxxx is currently out of the office but I will try to help with your enquiry.

We would normally advise using serum from the same species as the secondary antibody used is raise in. If your sec...

Read More

Thank you for your enquiry and your interest.

Would you be so kind to clarify and confirm your question:

- in which application you wish to use the antibody,

- you wish to know the concentration of the recommended blocking...

Read More

Thank you for contacting us.

I would be pleased to help you finding a suitable secondary antibody and a control for ab20874.

Could you please confirm what application you are going to perform and what conjugate is needed for the secon...

Read More

Thank you for contacting us and your interest in our products.

Unfortunately, none of the three antibodies you are interested in have been tested in in both the application you are interested in with rat samples and we do not have any other an...

Read More

Thank you for contacting us and for sending the questionnaire. The details provided enable us to closely monitor the quality of our products.

I am sorry this product did not perform as stated on the datasheet and for the inconvenience this has...

Read More

I am sorry this product did not perform as stated on the datasheet and for the inconvenience this has caused. As requested, I have issued a free of charge replacement for one vial of ab20874.

To check the status of the order please contact o...

Read More

I have looked into the following orders and have found that the vials provided again came from the same stock: Order number xxxxx (PO number xxxxx) of 30th March 2010 lot number  xxxxx Order number xxxxx (PO number xxxxx) of 19th of January 2010 ...

Read More

Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"